RU96103652A - NICOTINE-CONTAINING TABLET (OPTIONS), METHOD OF TREATMENT FOR SMOKING (OPTIONS), METHOD FOR REDUCING NICOTINE ADDICTION - Google Patents

NICOTINE-CONTAINING TABLET (OPTIONS), METHOD OF TREATMENT FOR SMOKING (OPTIONS), METHOD FOR REDUCING NICOTINE ADDICTION

Info

Publication number
RU96103652A
RU96103652A RU96103652/14A RU96103652A RU96103652A RU 96103652 A RU96103652 A RU 96103652A RU 96103652/14 A RU96103652/14 A RU 96103652/14A RU 96103652 A RU96103652 A RU 96103652A RU 96103652 A RU96103652 A RU 96103652A
Authority
RU
Russia
Prior art keywords
nicotine
buccal administration
containing tablet
craving
protocol
Prior art date
Application number
RU96103652/14A
Other languages
Russian (ru)
Other versions
RU2153338C2 (en
Inventor
Джиан Карло САНТУС
Original Assignee
Фармасиа АБ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/097,962 external-priority patent/US5549906A/en
Application filed by Фармасиа АБ filed Critical Фармасиа АБ
Publication of RU96103652A publication Critical patent/RU96103652A/en
Application granted granted Critical
Publication of RU2153338C2 publication Critical patent/RU2153338C2/en

Links

Claims (28)

1. Никотинсодержащая таблетка, отличающаяся тем, что включает никотин, абсорбирующий наполнитель и непитательный подсластитель.1. Nicotine-containing tablet, characterized in that it includes nicotine, an absorbent filler and a non-nutritive sweetener. 2. Никотинсодержащая таблетка по п.1, отличающаяся тем, что абсорбирующий наполнитель состоит из маннита. 2. Nicotine-containing tablet according to claim 1, characterized in that the absorbent filler consists of mannitol. 3. Никотинсодержащая таблетка по п.1, отличающаяся тем, что абсорбирующий наполнитель состоит из β- циклодекстрина. 3. Nicotine-containing tablet according to claim 1, characterized in that the absorbent filler consists of β-cyclodextrin. 4. Никотинсодержащая таблетка по п.1, 2 или 3, отличающаяся тем, что непитательный подсластитель состоит из ксилита. 4. Nicotine-containing tablet according to claim 1, 2 or 3, characterized in that the non-nutritive sweetener consists of xylitol. 5. Никотинсодержащая таблетка по п.4, отличающаяся тем, что она дополнительно содержит глицирризинат аммония. 5. Nicotine-containing tablet according to claim 4, characterized in that it further comprises ammonium glycyrrhizinate. 6. Никотинсодержащая таблетка по п.1, отличающаяся тем, что она имеет рН от 6 до 11. 6. Nicotine-containing tablet according to claim 1, characterized in that it has a pH from 6 to 11. 7. Никотинсодержащая таблетка, отличающаяся тем, что включает в себя никотин в количестве 0,5 - 5 мг; абсорбирующий наполнитель в количестве 5 - 15 мас. %, в котором наполнитель выбирают из группы, состоящей из маннита и β- циклодекстрина; непитательный подсластитель в количестве 80 - 90 мас.%, причем подсластитель состоит из ксилита; смазывающее вещество в количестве 0,1 - 5 мас.%; ароматизирующее вещество и буферное вещество в количестве, достаточном для регулирования рН таблетки от 6 до 11. 7. Nicotine-containing tablet, characterized in that it includes nicotine in an amount of 0.5 to 5 mg; absorbent filler in an amount of 5 to 15 wt. %, in which the filler is selected from the group consisting of mannitol and β-cyclodextrin; a non-nutritive sweetener in an amount of 80 to 90 wt.%, and the sweetener consists of xylitol; lubricant in an amount of 0.1 to 5 wt.%; a flavoring agent and a buffer substance in an amount sufficient to control the pH of the tablet from 6 to 11. 8. Никотинсодержащая таблетка по п.7, отличающаяся тем, что она дополнительно содержит глицирризинат аммония. 8. Nicotine-containing tablet according to claim 7, characterized in that it further comprises ammonium glycyrrhizinate. 9. Никотинсодержащая таблетка по п.7, отличающаяся тем, что она дополнительно содержит монофторфосфат или фторид натрия. 9. Nicotine-containing tablet according to claim 7, characterized in that it further comprises monofluorophosphate or sodium fluoride. 10. Никотинсодержащая таблетка по п.7, отличающаяся тем, что ароматизирующее вещество представляет собой комплекс включения циклодекстрина и ароматизирующего вещества эфирного масла. 10. Nicotine-containing tablet according to claim 7, characterized in that the flavoring substance is a inclusion complex of cyclodextrin and flavoring substance of essential oil. 11. Способ лечения от курения, отличающийся тем, что включает буккальное введение никотина пациенту, причем никотинсодержащая таблетка включает никотин и абсорбирующий наполнитель, при котором указанное буккальное введение никотина обеспечивает получение временных уровней никотина в крови в пределах 5 - 50 нг/мл. 11. A method of treating smoking, characterized in that it includes buccal administration of nicotine to a patient, the nicotine-containing tablet comprising nicotine and an absorbent excipient, wherein said buccal administration of nicotine provides temporary levels of nicotine in the blood in the range of 5-50 ng / ml. 12. Способ лечения от курения по п.11, отличающийся тем, что буккальное введение никотина приводит к максимальным уровням никотина в крови через 2 - 30 мин после буккального введения. 12. The method of treatment for smoking according to claim 11, characterized in that the buccal administration of nicotine leads to maximum levels of nicotine in the blood 2-30 minutes after buccal administration. 13. Способ лечения от курения по п.12, отличающийся тем, что буккальное введение никотина приводит к максимальным уровням никотина в крови через 2 - 10 мин после буккального введения. 13. The method of treatment for smoking according to item 12, wherein the buccal administration of nicotine leads to maximum levels of nicotine in the blood 2 to 10 minutes after buccal administration. 14. Способ лечения от курения по п.11, отличающийся тем, что буккальное введение никотина, обеспечиваемое путем предоставления никотинсодержащей таблетке возможности полностью раствориться во рту, приводит к максимальным уровням никотина в крови через 2 - 10 мин после буккального введения. 14. The method of treatment for smoking according to claim 11, characterized in that the buccal administration of nicotine, provided by allowing the nicotine-containing tablet to completely dissolve in the mouth, leads to maximum levels of nicotine in the blood 2-10 minutes after buccal administration. 15. Способ лечения от курения, отличающийся тем, что включает буккальное введение пациенту никотинсодержащей таблетки, при этом указанная таблетка содержит никотин, абсорбирующий наполнитель, при котором буккальное введение никотинсодержащей таблетки приводит к снижению тяги пациента к никотину, что замеряется согласно протоколу тяги к никотину. 15. A method of treating smoking, characterized in that it includes buccal administration of a nicotine-containing tablet to a patient, said tablet containing nicotine, an absorbent filler, wherein buccal administration of a nicotine-containing tablet reduces the patient's craving for nicotine, which is measured according to the nicotine craving protocol. 16. Способ по п.15, отличающийся тем, что дополнительно включает оценку непосредственно перед буккальным введением никотинсодержащей таблетки начальной тяги пациента к никотину с использованием протокола тяги к никотину, при котором указанный протокол тяги к никотину выбирают из группы, состоящей из протокола, приведенного в документе DSM-III-R, Шкалы тяги Шиффмана-Ярвика и Вопросника по тяге, и последующую за буккальным введением никотинсодержащей таблетки оценку дальнейшей тяги пациента к никотину при замере с помощью указанного протокола тяги, при котором буккальное введение никотинсодержащей таблетки приводит к максимальному уменьшению тяги пациента к никотину при замере с помощью указанного протокола тяги к никотину, через 2 - 30 мин после буккального введения никотинсодержащей таблетки. 16. The method according to clause 15, characterized in that it further includes evaluating immediately before the buccal administration of the nicotine-containing tablet the patient's initial craving for nicotine using the nicotine craving protocol, wherein said nicotine craving protocol is selected from the group consisting of the protocol given in DSM-III-R, Schiffman-Järvik Traction Scales and Traction Questionnaire, and subsequent evaluation after buccal administration of a nicotine-containing tablet, further traction of the patient for nicotine when measured using the protocol traction, in which buccal administration of a nicotine-containing tablet leads to a maximum decrease in the patient's craving for nicotine when measured using the specified nicotine-craving protocol, 2-30 minutes after buccal administration of a nicotine-containing tablet. 17. Способ уменьшения тяги к никотину, отличающийся тем, что включает буккальное введение пациенту никотинсодержащей таблетки, при этом таблетка содержит никотин, абсорбирующий наполнитель и непитательный подсластитель, при котором буккальное введение никотинсодержащей таблетки приводит к уменьшению тяги пациента к никотину, что замеряют с помощью протокола тяги к никотину. 17. A method of reducing craving for nicotine, characterized in that it includes buccal administration of a nicotine-containing tablet to a patient, the tablet containing nicotine, an absorbent filler and a non-nutritive sweetener, wherein buccal administration of a nicotine-containing tablet reduces the patient's craving for nicotine, which is measured using a protocol cravings for nicotine. 18. Способ по п.17, отличающийся тем, что дополнительно включает оценку непосредственно перед буккальным введением никотинсодержащей таблетки начальной тяги пациента к никотину, используя протокол тяги к никотину, при этом протокол тяги к никотину выбирают из группы, состоящей из протокола, приведенного в документе DSM-III-R, Шкалы тяги Шиффмана-Ярвика и Вопросника по тяге, и последующую за буккальным введением никотинсодержащей таблетки оценку дальнейшей тяги пациента к никотину, используя протокол тяги к никотину, при котором буккальное введение никотинсодержащей таблетки приводит к максимальному уменьшению тяги к никотину, что замеряют с помощью протокола тяги к никотину, через 2 - 30 мин после буккального введения никотинсодержащей таблетки. 18. The method according to 17, characterized in that it further includes evaluating immediately before the buccal administration of the nicotine-containing tablet the patient's initial craving for nicotine using the nicotine craving protocol, wherein the nicotine craving protocol is selected from the group consisting of the protocol described in the document DSM-III-R, Schiffman-Järvik Traction Scales and Traction Questionnaire, and subsequent evaluation after buccal administration of a nicotine-containing tablet, further patient craving for nicotine using the nicotine craving protocol, in which buccal injection Dilution of a nicotine-containing tablet leads to a maximum decrease in craving for nicotine, which is measured using the protocol of craving for nicotine, 2 to 30 minutes after buccal administration of a nicotine-containing tablet. 19. Способ по п. 16 или 18, отличающийся тем, что буккальное введение никотинсодержащей таблетки приводит к снижению по крайней мере на одну единицу тяги при замере с помощью протокола, приведенного в документе DSM-III-R. 19. The method according to p. 16 or 18, characterized in that the buccal administration of a nicotine-containing tablet results in a decrease of at least one unit of traction during measurement using the protocol described in DSM-III-R. 20. Способ по п. 16 или 18, отличающийся тем, что буккальное введение никотинсодержащей таблетки приводит к снижению тяги по крайней мере на одну единицу при замере с помощью Шкалы тяги Шиффмана-Ярвика. 20. The method according to p. 16 or 18, characterized in that the buccal administration of a nicotine-containing tablet leads to a decrease in traction by at least one unit when measured using a Schiffman-Järvik traction scale. 21. Способ по п. 16 или 18, отличающийся тем, что буккальное введение никотинсодержащей таблетки приводит к снижению тяги по крайней мере на три единицы при замере с помощью Вопросника по тяге. 21. The method according to p. 16 or 18, characterized in that the buccal administration of a nicotine-containing tablet leads to a decrease in traction by at least three units when measured using the Traction Questionnaire. 22. Способ по п. 16 или 18, отличающийся тем, что буккальное введение никотина приводит к максимальному снижению тяги пациента к никотину через 2 - 10 мин после буккального введения никотина. 22. The method according to p. 16 or 18, characterized in that the buccal administration of nicotine leads to a maximum reduction in patient craving for nicotine 2-10 minutes after buccal administration of nicotine. 23. Способ по п. 15 или 17, отличающийся тем, что буккальное введение никотина, обеспечиваемое путем предоставления никотинсодержащей таблетке возможности полностью раствориться во рту, приводит к максимальному снижению тяги пациента к никотину через 2 - 10 мин после буккального введения. 23. The method according to p. 15 or 17, characterized in that the buccal administration of nicotine, provided by allowing the nicotine-containing tablet to completely dissolve in the mouth, leads to a maximum reduction in patient craving for nicotine 2-10 minutes after buccal administration. 24. Способ по п.11, 15 или 17, отличающийся тем, что абсорбирующий наполнитель состоит из маннита. 24. The method according to claim 11, 15 or 17, characterized in that the absorbent filler consists of mannitol. 25. Способ по п.1, 15 или 17, отличающийся тем, что абсорбирующий наполнитель состоит из β- циклодекстрина. 25. The method according to claim 1, 15 or 17, characterized in that the absorbent filler consists of β-cyclodextrin. 26. Способ по п.11, 15, 17, 24 или 25, отличающийся тем, что непитательный подсластитель состоит из ксилита. 26. The method according to claim 11, 15, 17, 24 or 25, characterized in that the non-nutritive sweetener consists of xylitol. 27. Способ по п.26, отличающийся тем, что непитательный подсластитель дополнительно содержит глицирризинат аммония. 27. The method according to p, characterized in that the non-nutritive sweetener further comprises ammonium glycyrrhizinate. 28. Способ по п.11, 15 или 17, отличающийся тем, что никотинсодержащие таблетки имеют рН от 6 до 11. 28. The method according to claim 11, 15 or 17, characterized in that the nicotine-containing tablets have a pH from 6 to 11.
RU96103652/14A 1993-07-26 1994-07-20 Nicotine-containing tablet and method of treatment of patient with tobacco smoking addiction RU2153338C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/097962 1993-07-26
US08/097,962 US5549906A (en) 1993-07-26 1993-07-26 Nicotine lozenge and therapeutic method for smoking cessation

Publications (2)

Publication Number Publication Date
RU96103652A true RU96103652A (en) 1998-05-20
RU2153338C2 RU2153338C2 (en) 2000-07-27

Family

ID=22265948

Family Applications (2)

Application Number Title Priority Date Filing Date
RU96103652/63K RU2311210C2 (en) 1993-07-26 1994-07-20 Nicotine-containing tablet and method for treating against smoking
RU96103652/14A RU2153338C2 (en) 1993-07-26 1994-07-20 Nicotine-containing tablet and method of treatment of patient with tobacco smoking addiction

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU96103652/63K RU2311210C2 (en) 1993-07-26 1994-07-20 Nicotine-containing tablet and method for treating against smoking

Country Status (19)

Country Link
US (3) US5549906A (en)
EP (2) EP1666030B1 (en)
JP (2) JPH09505553A (en)
KR (1) KR100341340B1 (en)
CN (1) CN1109542C (en)
AT (1) ATE515257T1 (en)
AU (1) AU691826B2 (en)
CA (1) CA2166394C (en)
DK (1) DK0707478T3 (en)
ES (1) ES2369060T3 (en)
FI (1) FI960324A0 (en)
HU (1) HUT74920A (en)
NO (1) NO960313D0 (en)
NZ (1) NZ269670A (en)
PL (1) PL175988B1 (en)
PT (1) PT707478E (en)
RU (2) RU2311210C2 (en)
UA (1) UA41369C2 (en)
WO (1) WO1995003050A2 (en)

Families Citing this family (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525351A (en) * 1989-11-07 1996-06-11 Dam; Anders Nicotine containing stimulant unit
US5549906A (en) 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5889028A (en) * 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
WO1997042941A2 (en) 1996-05-13 1997-11-20 Novartis Consumer Health S.A. Buccal delivery system
FR2758459B1 (en) * 1997-01-17 1999-05-07 Pharma Pass FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIODAVAILABILITY AND PROCESS FOR PREPARING THE SAME
US6166032A (en) * 1997-02-07 2000-12-26 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US5760049A (en) * 1997-02-21 1998-06-02 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
JP3236249B2 (en) 1997-09-03 2001-12-10 廣次 野原 Oil-water emulsion fuel
US6908631B1 (en) 1997-12-01 2005-06-21 Nicogen, Inc. Therapeutic and diagnostic methods dependent on CYP2A enzymes
US6211194B1 (en) * 1998-04-30 2001-04-03 Duke University Solution containing nicotine
US6268386B1 (en) * 1998-06-25 2001-07-31 Marshall Anlauf Thompson Nicotine beverage
US6344222B1 (en) 1998-09-03 2002-02-05 Jsr Llc Medicated chewing gum delivery system for nicotine
US6358060B2 (en) 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
US6224897B1 (en) 1998-09-29 2001-05-01 Novartis Consumer Health S.A. Methods to abate the use of tobacco by humans
SE9803986D0 (en) 1998-11-23 1998-11-23 Pharmacia & Upjohn Ab New compositions
US6242473B1 (en) 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6248760B1 (en) * 1999-04-14 2001-06-19 Paul C Wilhelmsen Tablet giving rapid release of nicotine for transmucosal administration
US6409991B1 (en) * 1999-12-15 2002-06-25 Mark Reynolds Treatment and system for nicotine withdrawal
US6749882B2 (en) * 2000-05-17 2004-06-15 Stephen Fortune, Jr. Coffee having a nicotine composition dissolved therein
AU2001261744A1 (en) * 2000-05-19 2001-12-03 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
KR100381622B1 (en) * 2000-08-30 2003-04-26 디디에스텍주식회사 Irritating-reduced oral delivery formulations of basic drugs
AR033444A1 (en) * 2001-03-26 2003-12-17 Smithkline Beecham Corp SOLID DOSAGE FORM FOR THE ORAL ADMINISTRATION OF AN ACTIVE NICOTINE COMPOUND, THROUGH THE MUCOSE AND USE OF AN ACTIVE NICOTINE COMPOUND TO PREPARE IT
NZ530439A (en) * 2001-04-20 2004-11-26 Lavipharm Lab Inc Intraoral delivery of nicotine for smoking cessation
US6668839B2 (en) 2001-05-01 2003-12-30 Jonnie R. Williams Smokeless tobacco product
WO2002087365A1 (en) * 2001-05-01 2002-11-07 Williams Jonnie R Smokeless tobacco product
US20040020503A1 (en) * 2001-05-01 2004-02-05 Williams Jonnie R. Smokeless tobacco product
SE0102197D0 (en) * 2001-06-20 2001-06-20 Pharmacia Ab New product and use and manufacture thereof
SE521512C2 (en) * 2001-06-25 2003-11-11 Niconovum Ab Device for administering a substance to the front of an individual's oral cavity
SE0103211D0 (en) * 2001-09-27 2001-09-27 Pharmacia Ab New formulations and use thereof
SE0103210D0 (en) * 2001-09-27 2001-09-27 Pharmacia Ab New formulations and use thereof
US20030087937A1 (en) * 2001-10-15 2003-05-08 Nils-Olof Lindberg Nicotine and cocoa powder compositions
US20030119879A1 (en) * 2001-10-15 2003-06-26 Thomas Landh Nicotine and chocolate compositions
US20030091553A1 (en) * 2001-10-19 2003-05-15 Gehlsen Kurt R. Use of histamine to treat liver disease
US20030111088A1 (en) * 2001-10-29 2003-06-19 Addiction Therapies, Inc. Device and method for treating combination dependencies
CN1578650A (en) * 2001-11-06 2005-02-09 马克西姆医药公司 Compositions for the treatment of infectious diseases
US20100160376A1 (en) * 2001-12-10 2010-06-24 Marshall Anlauf Thompson Nicotine-alternative compositions and methods of producing such compositions
US20050131031A1 (en) * 2001-12-10 2005-06-16 Thompson Marshall A. Method of producing a nicotine composition
US20060204598A1 (en) * 2001-12-10 2006-09-14 Thompson Marshall A Nicotine-alternative compositions and methods of producing such compositions
US20030108592A1 (en) * 2001-12-10 2003-06-12 Thompson Marshall Anlauf Method of producing a nicotine composition
US20030159702A1 (en) * 2002-01-21 2003-08-28 Lindell Katarina E.A. Formulation and use manufacture thereof
US20030171408A1 (en) * 2002-03-11 2003-09-11 Caplan Jay L. Therapeutic method of delivering a medicament to avoid irritating effects on membranes of user
US20040101543A1 (en) * 2002-03-22 2004-05-27 John Liu Nicotine-containing oral dosage form
US7767698B2 (en) * 2002-06-03 2010-08-03 Mcneil Ab Formulation and use thereof
EP1534302A4 (en) * 2002-08-22 2009-01-07 Nutrition 21 Inc Arginine silicate inositol complex and use thereof
US20040052851A1 (en) * 2002-09-16 2004-03-18 Graff Allan H. Modified release oral dosage form
KR100443722B1 (en) * 2002-09-26 2004-08-09 이용원 Hard chewing candy comprising nicotine and its preparation
AU2002350090A1 (en) 2002-10-31 2004-06-07 Recovery Pharmaceuticals, Inc. Device and method for treating combination dependencies
US20040115244A1 (en) * 2002-12-17 2004-06-17 Holgate Eric Jamison Methods and compositions for nicotine replacement therapy
ATE359075T1 (en) 2002-12-20 2007-05-15 Niconovum Ab CHEMICALLY AND PHYSICALLY STABLE PARTICLE MATERIAL CONTAINING NICOTINE AND MICROCRYSTALLINE CELLULOSE
RU2342953C2 (en) 2003-02-24 2009-01-10 Фармасьютикал Продакшенз, Инк. Transmucosal system of delivery of medical products
US9498454B2 (en) 2003-02-24 2016-11-22 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US9358296B2 (en) 2003-02-24 2016-06-07 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
US9254294B2 (en) 2003-02-24 2016-02-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
US20040180110A1 (en) * 2003-03-14 2004-09-16 Atul Mistry Chewing gum and confectionery compositions containing an endothermic agent
US20070130132A1 (en) * 2003-06-30 2007-06-07 Business Objects Apparatus and method for personalized data delivery
US20050045197A1 (en) * 2003-08-28 2005-03-03 Gelder Steven K. Multiple drug delivery system & method
GB0320854D0 (en) 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
US20050123502A1 (en) * 2003-10-07 2005-06-09 Chan Shing Y. Nicotine containing oral compositions
WO2005046363A2 (en) * 2003-11-07 2005-05-26 U.S. Smokeless Tobacco Company Tobacco compositions
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US20050171192A1 (en) * 2003-12-11 2005-08-04 Gehlsen Kurt R. Use of histamine to treat bone disease
US20050234024A1 (en) * 2004-04-14 2005-10-20 Clarke David E Materials and methods for the treatment of ulcerative colitis
CN1332667C (en) * 2004-05-26 2007-08-22 中国科学院生物物理研究所 Compound preparation for resisting Parkinson's disease
CN1332666C (en) * 2004-05-26 2007-08-22 中国科学院生物物理研究所 Compound preparation for resisting senile dementia
US20060002913A1 (en) * 2004-06-22 2006-01-05 Gehlsen Kurt R Use of histamine and related compounds to treat disorders affecting muscle function
DE602005015446D1 (en) * 2004-06-29 2009-08-27 Fertin Pharma As TOBACCO ALCOHOL RELEASING CHEWING GUM
US7780981B2 (en) 2004-09-13 2010-08-24 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US7766018B2 (en) * 2004-09-30 2010-08-03 Smoke-Break, Inc. Device and composition for reducing the incidence of tobacco smoking
US20100092616A1 (en) * 2005-01-27 2010-04-15 Marshall Anlauf Thompson Method of producing a nicotine composition
CN101222861B (en) * 2005-04-29 2010-09-08 菲利普莫里斯生产公司 Tobacco pouch product
US9044049B2 (en) * 2005-04-29 2015-06-02 Philip Morris Usa Inc. Tobacco pouch product
US20060264455A1 (en) * 2005-05-23 2006-11-23 Schachter Steven C Use of huperzine for disorders
BRPI0611035A2 (en) * 2005-05-25 2010-08-10 Us Smokeless Tobacco Co tobacco compositions
JP2009502436A (en) * 2005-08-02 2009-01-29 バクスター・インターナショナル・インコーポレイテッド Multi-chamber container
US8685478B2 (en) 2005-11-21 2014-04-01 Philip Morris Usa Inc. Flavor pouch
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US20070267033A1 (en) * 2006-02-09 2007-11-22 Philip Morris Usa Inc. Gamma cyclodextrin flavoring-release additives
AU2007224586A1 (en) * 2006-03-16 2007-09-20 Niconovum Ab Stable lozenge compositions providing rapid release of nicotine
EP1998748B1 (en) 2006-03-16 2015-01-14 NicoNovum AB Improved snuff composition
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
US8642016B2 (en) 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
WO2008069921A2 (en) * 2006-12-01 2008-06-12 Cima Labs Inc. Oral transmucosal nicotine dosage form
US20090214442A1 (en) * 2006-12-01 2009-08-27 Cephalon, Inc. Oral Transmucosal Nicotine Dosage Form
US20100197625A1 (en) 2006-12-21 2010-08-05 D Alarcao Marc Synthetic lipophilic inositol glycans for treatment of cancer and glucose-metabolism disorders
US8616221B2 (en) 2007-02-28 2013-12-31 Philip Morris Usa Inc. Oral pouch product with flavored wrapper
US20080230078A1 (en) * 2007-03-19 2008-09-25 Oby George Tolman Method of smoking cessation
KR101122469B1 (en) * 2007-04-02 2012-07-12 파킨슨즈 인스티튜트 Methods and compositions for reduction of side effects of therapeutic treatments
US9888712B2 (en) * 2007-06-08 2018-02-13 Philip Morris Usa Inc. Oral pouch products including a liner and tobacco beads
WO2009010884A2 (en) 2007-07-16 2009-01-22 Philip Morris Products S.A. Tobacco-free oral flavor delivery pouch product
WO2009010881A2 (en) * 2007-07-16 2009-01-22 Philip Morris Products S.A. Oral pouch products with immobilized flavorant particles
US8119173B2 (en) * 2007-07-16 2012-02-21 Philip Morris Usa Inc. Method of flavor encapsulation through the use of a drum coater
US8950408B2 (en) 2007-07-16 2015-02-10 Philip Morris Usa Inc. Oral pouch product having soft edge
US20090081291A1 (en) * 2007-09-26 2009-03-26 Gin Jerry B Sustained Release Dosage Forms For Delivery of Agents to an Oral Cavity of a User
US20090081294A1 (en) * 2007-09-26 2009-03-26 Gin Jerry B Sustained release dosage form for lubricating an oral cavity
EP2219479B1 (en) * 2007-12-21 2018-08-15 Swedish Match North Europe AB A tobacco or non-tobacco product comprising magnesium carbonate
CL2009001025A1 (en) 2008-05-01 2010-09-24 Smithkline Beecham Corp Lozenge composition comprising: a) a standard granule with at least: an alkaline buffering agent, a dissolution modifier and a filler, b) a defined extragranular nicotine active ingredient and at least one alkaline buffering agent; preparation procedure; Useful to eliminate or reduce tobacco use.
ES2529297T3 (en) 2008-05-21 2015-02-18 Novartis Ag Pressable chewing gums comprising nicotine and a buffering agent
US9700525B2 (en) 2008-08-20 2017-07-11 Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College Continuous local slow-release of therapeutics for head and neck problems and upper aerodigestive disorders
US20100055050A1 (en) * 2008-08-30 2010-03-04 Kathleen Moore Nicotine chewing gum on a stick
WO2010028134A2 (en) * 2008-09-04 2010-03-11 President And Fellows Of Harvard College Treatment of neurological disorders using huperzine
US8377215B2 (en) 2008-12-18 2013-02-19 Philip Morris Usa Inc. Moist botanical pouch processing
EP2213181A1 (en) * 2009-01-28 2010-08-04 Philip Morris Products S.A. Smokeless dissolvable compressed tobacco product
US8863755B2 (en) 2009-02-27 2014-10-21 Philip Morris Usa Inc. Controlled flavor release tobacco pouch products and methods of making
US20110038915A1 (en) * 2009-08-14 2011-02-17 Eduardo Jose Gonzalez Chewing Gum Formula for Enhancing Psycho-Spirituality
US8747562B2 (en) 2009-10-09 2014-06-10 Philip Morris Usa Inc. Tobacco-free pouched product containing flavor beads providing immediate and long lasting flavor release
WO2011084376A1 (en) * 2009-12-21 2011-07-14 Rock Creek Pharmaceuticals, Inc. Smoking cessation lozenge containing tobacco alkaloid and silver salt
US20110186062A1 (en) * 2010-02-01 2011-08-04 Carra Leah Hood Smoking risk reduction/reduction to quit/cessation aid
KR20130008535A (en) * 2010-02-18 2013-01-22 자틴 바산트 타카르 Nicotine-containing soft gelatin pastilles
US20110268809A1 (en) 2010-04-28 2011-11-03 Paul Andrew Brinkley Nicotine-Containing Pharmaceutical Compositions
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
UA112974C2 (en) 2010-09-16 2016-11-25 Джеі. Бі. Кемікалс Енд Фармасьютікалс Лімітид NICOTINE COMPOSITION (OPTIONS)
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst Compositions and methods for treatment of symptoms in parkinson's disease patients
CN103763953B (en) 2011-09-06 2016-08-17 英美烟草(投资)有限公司 Heating smokeable material
US9474303B2 (en) 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US20130177646A1 (en) * 2012-01-05 2013-07-11 Mcneil Ab Solid Nicotine-Comprising Dosage Form with Reduced Organoleptic Disturbance
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
US9044035B2 (en) 2012-04-17 2015-06-02 R.J. Reynolds Tobacco Company Remelted ingestible products
US9456916B2 (en) 2013-03-12 2016-10-04 Medibotics Llc Device for selectively reducing absorption of unhealthy food
GB201217067D0 (en) 2012-09-25 2012-11-07 British American Tobacco Co Heating smokable material
GB201302485D0 (en) 2013-02-13 2013-03-27 British American Tobacco Co Tobacco Treatment
US20140255452A1 (en) 2013-03-11 2014-09-11 Niconovum Usa, Inc. Method and apparatus for differentiating oral pouch products
US9067070B2 (en) 2013-03-12 2015-06-30 Medibotics Llc Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type
US9011365B2 (en) 2013-03-12 2015-04-21 Medibotics Llc Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food
TW201507726A (en) 2013-05-10 2015-03-01 Glaxosmithkline Llc Nicotine lozenge formulation
GB201311620D0 (en) 2013-06-28 2013-08-14 British American Tobacco Co Devices Comprising a Heat Source Material and Activation Chambers for the Same
JP5730355B2 (en) * 2013-07-24 2015-06-10 学校法人近畿大学 CYP2A13 inhibitor
GB201314917D0 (en) 2013-08-21 2013-10-02 British American Tobacco Co Treated Tobacco and processes for preparing the same, Devices including the same and uses thereof
US11503853B2 (en) * 2013-09-09 2022-11-22 R.J. Reynolds Tobacco Company Smokeless tobacco composition incorporating a botanical material
US9999243B2 (en) * 2013-10-03 2018-06-19 Altria Client Services Llc Exhausted tobacco lozenge
US10105320B2 (en) 2013-10-03 2018-10-23 Altria Client Services Soluble fiber lozenge
US10244786B2 (en) 2013-10-03 2019-04-02 Altria Client Services Llc Tobacco lozenge
US10357054B2 (en) 2013-10-16 2019-07-23 R.J. Reynolds Tobacco Company Smokeless tobacco pastille
US20150174079A1 (en) * 2013-12-24 2015-06-25 Food for Health International, LLC Lozenges with silver nanoparticles
WO2015183801A1 (en) 2014-05-27 2015-12-03 R. J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
GB201500582D0 (en) 2015-01-14 2015-02-25 British American Tobacco Co Apparatus for heating or cooling a material contained therein
GB2535427A (en) 2014-11-07 2016-08-24 Nicoventures Holdings Ltd Solution
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US10881133B2 (en) 2015-04-16 2021-01-05 R.J. Reynolds Tobacco Company Tobacco-derived cellulosic sugar
US11924930B2 (en) 2015-08-31 2024-03-05 Nicoventures Trading Limited Article for use with apparatus for heating smokable material
US20170055584A1 (en) 2015-08-31 2017-03-02 British American Tobacco (Investments) Limited Article for use with apparatus for heating smokable material
US20170055575A1 (en) 2015-08-31 2017-03-02 British American Tobacco (Investments) Limited Material for use with apparatus for heating smokable material
US10869497B2 (en) 2015-09-08 2020-12-22 R.J. Reynolds Tobacco Company High-pressure cold pasteurization of tobacco material
US20170119046A1 (en) 2015-10-30 2017-05-04 British American Tobacco (Investments) Limited Apparatus for Heating Smokable Material
US20170119047A1 (en) 2015-10-30 2017-05-04 British American Tobacco (Investments) Limited Article for Use with Apparatus for Heating Smokable Material
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
CN108495563B (en) 2015-11-25 2022-04-26 R.J.雷诺兹烟草公司 Nicotine salts, co-crystals and salt co-crystal complexes
US10532046B2 (en) 2015-12-03 2020-01-14 Niconovum Usa, Inc. Multi-phase delivery compositions and products incorporating such compositions
US20170165252A1 (en) 2015-12-10 2017-06-15 Niconovum Usa Inc. Protein-enriched therapeutic composition
US11612183B2 (en) 2015-12-10 2023-03-28 R.J. Reynolds Tobacco Company Protein-enriched tobacco composition
CA2916077C (en) * 2015-12-22 2023-06-20 Euro-Pharm International Canada Inc. Nicotine-containing solid oral formulations and uses thereof
US10499684B2 (en) 2016-01-28 2019-12-10 R.J. Reynolds Tobacco Company Tobacco-derived flavorants
US11154087B2 (en) 2016-02-02 2021-10-26 R.J. Reynolds Tobacco Company Method for preparing flavorful compounds isolated from black liquor and products incorporating the flavorful compounds
CA3035584A1 (en) 2016-09-01 2018-03-08 Jds Therapeutics, Llc Magnesium biotinate compositions and methods of use
JP2020503950A (en) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Device and method for transdermal drug delivery
US11091446B2 (en) 2017-03-24 2021-08-17 R.J. Reynolds Tobacco Company Methods of selectively forming substituted pyrazines
EP3634387B1 (en) 2017-05-22 2024-01-17 Johnson & Johnson Consumer Inc. Lozenge dosage form
WO2019049049A1 (en) 2017-09-05 2019-03-14 R. J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
CN108323791B (en) * 2018-01-03 2021-02-12 云南中烟工业有限责任公司 Nicotine-zinc oxide compound, preparation method thereof and tobacco product containing nicotine-zinc oxide compound
US20190307082A1 (en) 2018-04-05 2019-10-10 R.J. Reynolds Tobacco Company Oriental tobacco production methods
JP7420797B2 (en) 2018-05-29 2024-01-23 モーニングサイド ベンチャー インベストメンツ リミテッド Drug delivery methods and systems
EP3807260A1 (en) 2018-06-15 2021-04-21 R. J. Reynolds Tobacco Company Purification of nicotine
JP2022515314A (en) 2018-11-02 2022-02-18 ニュートリション・２１，エルエルシー Composition for improving cognitive function of video game players containing inositol-stabilized arginine silicate complex and inositol
LU101519B1 (en) 2019-12-02 2021-06-07 Herrera Arturo Solis (S)-3-[1-MethyIpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a solid substance and a tablet
WO2021116855A1 (en) 2019-12-09 2021-06-17 Nicoventures Trading Limited Oral compositions and methods of manufacture
WO2021116865A1 (en) 2019-12-09 2021-06-17 Nicoventures Trading Limited Agents for oral composition
CA3165102A1 (en) 2019-12-16 2021-06-24 Nutrition 21, Llc Methods of production of arginine-silicate complexes
WO2022189977A1 (en) 2021-03-09 2022-09-15 Nicoventures Trading Limited Oral products and methods of manufacture
US20220354785A1 (en) 2021-04-22 2022-11-10 Nicoventures Trading Limited Oral lozenge products
AU2022268733A1 (en) 2021-05-06 2023-12-21 Nicoventures Trading Limited Oral compositions and related methods for reducing throat irritation
WO2023053062A1 (en) 2021-09-30 2023-04-06 Nicoventures Trading Limited Oral product with a basic amine and an ion pairing agent
US20230148660A1 (en) 2021-11-15 2023-05-18 Nicoventures Trading Limited Products with enhanced sensory characteristics
WO2023248187A1 (en) 2022-06-24 2023-12-28 Nicoventures Trading Limited Oral composition comprising a receptor modulator
WO2024074839A1 (en) 2022-10-07 2024-04-11 Nicoventures Trading Limited Oral product
GB202214771D0 (en) 2022-10-07 2022-11-23 Nicoventures Trading Ltd Oral product
WO2024074842A1 (en) 2022-10-07 2024-04-11 Nicoventures Trading Limited Oral product
WO2024074843A1 (en) 2022-10-07 2024-04-11 Nicoventures Trading Limited Oral product
GB202214775D0 (en) 2022-10-07 2022-11-23 Nicoventures Trading Ltd Oral product
GB202214803D0 (en) 2022-10-07 2022-11-23 Nicoventures Trading Ltd Oral product
WO2024095163A1 (en) 2022-11-01 2024-05-10 Nicoventures Trading Limited Oral composition comprising encapsulated ph adjusting agent
WO2024097549A1 (en) * 2022-11-03 2024-05-10 Nic Nac Naturals, Llc Composition and method for controlled human nicotine absorption without ph adjusters
WO2024095011A1 (en) 2022-11-04 2024-05-10 Nicoventures Trading Limited Oral product
GB202216465D0 (en) 2022-11-04 2022-12-21 Nicoventures Trading Ltd Oral product

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282706A (en) 1964-11-23 1966-11-01 Macandrews & Forbes Company Sucrose-ammoniated glycyrrhizin sweetening agent
US3717711A (en) * 1970-06-22 1973-02-20 Hoffmann La Roche Reducing fatty acid synthesis with a diet containing xylitol
US3901248A (en) 1970-07-22 1975-08-26 Leo Ab Chewable smoking substitute composition
US3877468A (en) 1970-07-22 1975-04-15 Leo Ab Chewable tobacco substitute composition
US3845217A (en) 1972-11-16 1974-10-29 Helsingborg L Ab Buffered smoking substitute compositions
US4254154A (en) 1978-10-30 1981-03-03 Cumberland Packing Corp. Dipeptide sweetener compositions
US4317837A (en) 1980-11-25 1982-03-02 Life Savers, Inc. Tobacco-flavored chewing gum
GB8317576D0 (en) * 1983-06-29 1983-08-03 Shaw A S W Consumer tobacco products
GB2142822B (en) * 1983-06-29 1987-02-11 Alec Stanley Walter Shaw Nicotine lozenges
US5092352A (en) 1983-12-14 1992-03-03 American Brands, Inc. Chewing tobacco product
BE899037A (en) * 1984-02-29 1984-06-18 Trenker Ady Nicotine compsn. to help people to stop smoking - is a tablet for sucking, which contains nicotine or its water-soluble acid salt
US4767808A (en) * 1984-10-05 1988-08-30 Hercon Laboratories Corporation Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant
DE3506406A1 (en) * 1985-02-23 1986-08-28 Hans-Josef 5600 Wuppertal Stromberg DEVICE FOR THE DEWNING OF EATING, DRINKING, SMOKING AND / OR ADDICTIVE Habits
US5016652A (en) * 1985-04-25 1991-05-21 The Regents Of The University Of California Method and apparatus for aiding in the reduction of incidence of tobacco smoking
US4953572A (en) * 1985-04-25 1990-09-04 Rose Jed E Method and apparatus for aiding in the reduction of incidence of tobacco smoking
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4800903A (en) * 1985-05-24 1989-01-31 Ray Jon P Nicotine dispenser with polymeric reservoir of nicotine
US4753800A (en) * 1985-10-04 1988-06-28 Warner-Lambert Company Medicament adsorbates and their preparation
US5055478A (en) * 1986-06-19 1991-10-08 Cooper Thomas M Method for stopping smoking
DE3639418A1 (en) * 1986-11-18 1988-06-09 Forschungsgesellschaft Rauchen NICOTINE-BASED AGENT
CA1273878A (en) * 1987-01-15 1990-09-11 Richard Philip Moody Nicotine-containing preparation for transdermal administration
IL86170A (en) * 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
US4837027A (en) * 1987-11-09 1989-06-06 Alza Corporation Transdermal drug delivery device
US5174989A (en) * 1987-11-25 1992-12-29 Shiseido Company Ltd. Oral composition
US5004601A (en) * 1988-10-14 1991-04-02 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5139790A (en) * 1988-10-14 1992-08-18 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5135752A (en) * 1988-10-14 1992-08-04 Zetachron, Inc. Buccal dosage form
US5013716A (en) 1988-10-28 1991-05-07 Warner-Lambert Company Unpleasant taste masking compositions and methods for preparing same
GB8828468D0 (en) * 1988-12-06 1989-01-05 Stoppers Co Ltd Nicotine containing lozenge
IE62662B1 (en) * 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
US4908213A (en) * 1989-02-21 1990-03-13 Schering Corporation Transdermal delivery of nicotine
GB2230439A (en) * 1989-04-20 1990-10-24 Alec Stanley Walter Shaw Nicotine lozenges
DK365389D0 (en) * 1989-07-24 1989-07-24 Fertin Lab As ANTIFUNGAL CHEMICAL GUM PREPARATION
ES2079485T3 (en) * 1989-08-25 1996-01-16 Bioglan Ireland R & D Ltd PHARMACEUTICAL COMPOSITIONS AND A DEVICE TO ADMINISTER THEM.
SE8904295D0 (en) * 1989-12-21 1989-12-21 Pharmacia Ab SMOKING SUBSTITUTE
US5077104A (en) 1989-12-21 1991-12-31 Alza Corporation Nicotine packaging materials
US5156845A (en) * 1990-05-04 1992-10-20 Colgate-Palmolive Company Dry mouth lozenge
US5135753A (en) * 1991-03-12 1992-08-04 Pharmetrix Corporation Method and therapeutic system for smoking cessation
GB9111224D0 (en) * 1991-05-24 1991-07-17 Charwell Consumer Prod Smoking substitute preparation
FR2685205A1 (en) 1991-12-23 1993-06-25 Ardeval Laboratoires SOLID - BASED PLANT COMPOSITION, PREPARATION METHOD AND APPLICATIONS THEREOF.
US5549906A (en) 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation

Similar Documents

Publication Publication Date Title
RU96103652A (en) NICOTINE-CONTAINING TABLET (OPTIONS), METHOD OF TREATMENT FOR SMOKING (OPTIONS), METHOD FOR REDUCING NICOTINE ADDICTION
Ekstrand et al. Pharmacokinetics of fluoride gels in children and adults
DE69012591T2 (en) Use of nicotine to make a kit for the treatment of disease conditions that respond to nicotine treatment.
Tonetti et al. Effect of cigarette smoking on periodontal healing following GTR in infrabony defects: a preliminary retrospective study
Mäkinen et al. Oral biochemical status and depression of Streptococcus mutans in children during 24-to 36-month use of xylitol chewing gum
Doenicke et al. A Comparison of Two Formulations for Etomidate, 2-Hydroxypropyl-$ bT-cyclodextrin (HPCD) and Propylene Glycol
JP3623962B2 (en) Pharmaceutical composition for intranasal administration of hydroxocobalamin
Smith et al. The efficacy of an anti‐gingivitis chewing gum
HU229565B1 (en) Analgesic compositions containing buprenorphine
US20070110683A1 (en) Oral care formulation
Loftsson et al. Topically effective ocular hypotensive acetazolamide and ethoxyzolamide formulations in rabbits
JP2010280702A (en) Stabilized formulation of alpha adrenergic receptor antagonists and use thereof
US5514366A (en) Dental and oral preparation for smokers for solubilizing and removing tobacco tars as well as onion and garlic essential oils
US5658554A (en) Mouth moistener for the relief of dry mouth condition
EP0621036B1 (en) Aqueous compositions comprising argatroban and cyclodextrin or caffeine
US7229630B2 (en) Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Fujisawa et al. Clinical efficacy and safety of sildenafil in elderly patients with erectile dysfunction
Reino et al. Comparative study of two surgical techniques for root coverage of large recessions in heavy smokers.
CA2011928A1 (en) Oral rinse compositions
Amin et al. An open-label, noncomparative study to evaluate the efficacy, safety, and tolerability of azithromycin in the treatment of patients with acute sinusitis
WO1993023045A1 (en) Use of cotinine to alleviate tobacco withdrawal syndrome
JPH07112933A (en) Stable conjugated vitamin solution for internal use
Temple et al. The buccal absorption characteristics of fomocaine
JPH1036252A (en) Oral liquid medicine combined with belladonna (total) alkaloid
JPH0635374B2 (en) Oral composition